CDMO Theragent has signed a multi-year agreement with AI-based software firm Insight68 to streamline and digitalize the cell therapy manufacturing process. Contract development manufacturing organization (CDMO) Theragent will have access to Insight68’s digital platform to scale manufacturing while managing production schedules with customers’ clinical trial schedules, derisking delivery of treatment to patient. Insight68’s platform has AI-driven capabilities, and the firm claims it can optimize and predict inventory, logistics, and production. Theragent said the platform tackles issues such as slow processing,…

The Bern facility forms part of a deal to acquire a portfolio of travel vaccines from Emergent Biosolutions and will strengthen Bavarian Nordic’s manufacturing network. Danish drugmaker Bavarian Nordic has struck a deal to buy numerous vaccine assets from Emergent, including the approved oral vaccines Vivotif and Vaxchora, for typhoid and cholera respectively. Bavarian Nordic will also add late-stage Chikungunya candidate, which could launch in 2025. The deal also bolsters Bavarian Nordic’s global footprint, with the firm set to add…